Can anyone tell me why the fuck Mankind which was trading at $2.60 yesterday decide to sell 2ndary IPO of 40 million shares (200 mil diluted outstanding most recent #s) + 30 million of warrants combined for $2? I get they are selling to their parent company but wtf is this shit.
Trending Content
| +81 | Q&A - Buyside Equity Research Analyst/PM | 29 | 9h | |
| +32 | How the heck do you learn all of this stuff? | 5 | 6d | |
| +28 | My experience on the sell side | 20 | 1w | |
| +28 | Getting Frustrated | 10 | 3w | |
| +26 | What’s my next move? | 8 | 4h | |
| +18 | Biotech ER vs IB | 16 | 3w | |
| +17 | Am i fairly compensated? | 8 | 1d | |
| +14 | Heard they don’t model at Oppenheimer | 10 | 1w | |
| +14 | Data Science to PM | 8 | 3d | |
| +13 | ER time line and ways to break in help | 17 | 3w |
Career Resources
Because they had $2mm of cash and over $400mm of debt...
You missed the pnt. They were trading at $2.60 but their secondary IPO is at $2.00 per share...
Actually, even worse if you consider the intrinsic value of the warrants which is ~$0.35 per unit... Thats the cost of trying to raise money when you're a biotech company and demand is weak . Although they'll receive no proceeds from the other offering that went to the CEO's holdco, at least that portion was at $2.59 and he will be paying additionally for the warrants.
If you take into consideration that both deals combined sold 80mm shares and raised $187.35mm gross proceeds, the effective offering price per share is $2.34. Unconventional way of looking at it, but makes the capital raise as a whole more palatable from the issuer standpoint.
Voluptatibus cum ea voluptatibus voluptas. Dolor dolor temporibus est officiis nobis. Omnis magni suscipit placeat porro possimus itaque modi.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...